We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.35%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.46B
AUM Growth
-$2.68M
Cap. Flow
-$106M
Cap. Flow %
-1.64%
Top 10 Hldgs %
39.36%
Holding
145
New
22
Increased
28
Reduced
21
Closed
17

Top Buys

Rank Stock Value
1
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$201M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$91.6M
3
QURE icon
uniQure
QURE
+$57.2M
4
NTRA icon
Natera
NTRA
+$47.4M
5
ATNX
Athenex, Inc. Common Stock
ATNX
+$47.3M

Top Sells

Rank Stock Value
1
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$272M
2
GH icon
Guardant Health
GH
+$118M
3
VTRS icon
Viatris
VTRS
+$77.1M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$64M
5
HUM icon
Humana
HUM
+$55.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.58%
2 Financials 1.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FLXN
126
DELISTED
Flexion Therapeutics, Inc.
FLXN
$1.11M 0.02%
+89,919
New +$1.04M
BLRX
127
BioLineRX
BLRX
$12.2M
$379K 0.01%
1,731
– –
XYLO
128
DELISTED
Xylo Technologies
XYLO
$37K ﹤0.01%
375
– –
AMRN
129
CALL
Amarin Corp
AMRN
$293M
– –
-17,500
Closed -$7.27M
ENTA icon
130
Enanta Pharmaceuticals
ENTA
$367M
– –
-233,100
Closed -$22.3M
GH icon
131
Guardant Health
GH
$19B
– –
-1,534,464
Closed -$118M
HRTX icon
132
Heron Therapeutics
HRTX
$92M
– –
-1,069,000
Closed -$26.1M
HUM icon
133
Humana
HUM
$46.7B
– –
-210,300
Closed -$55.9M
KALV
134
DELISTED
KalVista Pharmaceuticals
KALV
– –
-90,500
Closed -$2.59M
TEVA icon
135
Teva Pharmaceuticals
TEVA
$36.9B
– –
-4,079,000
Closed -$64M
WVE icon
136
PUT
Wave Life Sciences
WVE
$1.13B
– –
-180,000
Closed -$6.99M
ONC
137
BeOne Medicines Ltd
ONC
$34.3B
– –
-282,500
Closed -$37.3M
SCTL
138
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
– –
-48,501
Closed -$255K
CBAY
139
DELISTED
Cymabay Therapeutics
CBAY
– –
-1,874,955
Closed -$24.9M
NVTA
140
DELISTED
Invitae Corporation
NVTA
– –
-222,017
Closed -$5.2M
AERI
141
DELISTED
Aerie Pharmaceuticals
AERI
– –
-58,000
Closed -$2.75M
SRRA
142
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-7,928
Closed -$542K
WMGI
143
CALL
DELISTED
Wright Medical Group Inc
WMGI
– –
-250,000
Closed -$7.86M
CMTA
144
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
– –
-10,425,225
Closed -$272M
CELG
145
DELISTED
Celgene Corp
CELG
– –
-295,000
Closed -$27.8M
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2019 Portfolio in Review

As of Q2 2019, OrbiMed held 145 positions worth $6.46B, down 0.04% from $6.46B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

OrbiMed's Q2 2019 filing shows 22 new, 28 increased, 21 reduced and 17 closed positions. Its largest new stake was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M. The largest sale was Clementia Pharmaceuticals Inc., an estimated $272M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q2 2019 buy was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M.
  • OrbiMed added most to Natera in Q2 2019, an estimated $47.4M increase.
  • OrbiMed's biggest Q2 2019 reduction was Viatris, cutting an estimated $77.1M.
  • OrbiMed fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $272M.
  • OrbiMed's ten largest holdings make up 39% of its $6.46B portfolio in Q2 2019.
  • OrbiMed opened 22 new positions and closed 17 in Q2 2019.
  • OrbiMed's portfolio value fell 0.04% quarter-over-quarter to $6.46B.

Based on OrbiMed's 13F filing for Q2 2019, filed 14 Aug 2019.